Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
Theravance has received two complete response letters but says it does not plan to do additional clinical studies for the new indication; Vibativ production has been halted in the U.S. and its marketing authorization withdrawn in Europe.